加载中...

AbbVie Inc. (ABBV) 财务分析 | 估值·财报 | 100Baggers.club

AbbVie Inc.

ABBV

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

加载图表中...

加载图表中...

📊 估值

关键估值指标

EV/EBITDA (TTM)

i

Enterprise Value, EBITDA and Ratio

EV/EBIT (TTM)

i

Enterprise Value, EBIT and Ratio

EV/Sales (TTM)

i

Enterprise Value, Revenue and Ratio

P/E Ratio (TTM)

i

Market Cap, Net Income and Ratio

P/B Ratio (Quarterly)

i

Market Cap, Book Value and Ratio

FCF Yield (TTM)

i

FCF, Enterprise Value and Yield

PR Profit Ratio (PPM)

i

PE Ratio, ROE and Profit Ratio (PR = PE / ROE)

📈 成长

营收、盈利和每股成长指标

Revenue (Quarterly)

i

Quarterly Revenue

Revenue/Share (Quarterly)

i

Revenue Per Share

Net Income (Quarterly)

i

Quarterly Net Income

EPS (Quarterly)

i

Earnings Per Share

Gross Profit/Share (Quarterly)

i

Gross Profit Per Share

OCF/Share (Quarterly)

i

Operating Cash Flow Per Share

FCF/Share (Quarterly)

i

Free Cash Flow Per Share

Operating Leverage (YoY)

i

Change in Operating Income / Change in Revenue

💰 盈利

利润率和净资产收益率

Gross Margin (TTM)

i

Revenue, Gross Profit and Gross Margin

Operating Margin (TTM)

i

Revenue, Operating Income and Operating Margin

Net Profit Margin (TTM)

i

Revenue, Net Income and Net Profit Margin

ROE (TTM)

i

Equity, Net Income and Return on Equity

ROA (TTM)

i

Assets, Net Income and Return on Assets

ROTCE - Return on Tangible Common Equity (TTM)

i

Net Income, Tangible Common Equity and ROTCE

OCF Margin (TTM)

i

Revenue, Operating Cash Flow and OCF Margin

FCF Margin (TTM)

i

Revenue, Free Cash Flow and FCF Margin

💵 现金质量

现金流质量和转换指标

OCF/NI Ratio (TTM)

i

Operating Cash Flow, Net Income and Ratio

FCF/NI Ratio (TTM)

i

Free Cash Flow, Net Income and Ratio

OCF/Capex (TTM)

i

Operating Cash Flow, Capex and Coverage Ratio

OCF/SBC (TTM)

i

Operating Cash Flow, SBC and Coverage Ratio

🛡️ 财务韧性

债务、流动性和财务健康度

Debt/Equity (quarterly)

i

Total Debt, Total Equity and Debt/Equity Ratio

EBITDA/Net Debt (TTM)

i

EBITDA, Net Debt and Coverage Ratio

Interest Coverage (TTM)

i

EBIT, Interest Expense and Coverage Ratio

Current Ratio (quarterly)

i

Current Assets, Current Liabilities and Current Ratio

Quick Ratio (quarterly)

i

Quick Assets, Current Liabilities and Quick Ratio

Altman Z-Score

i

Financial Distress Prediction Model

⚙️ 运营与资本效率

资产利用率、营运资本、ROIC和资本效率

ROIC (TTM)

i

NOPAT, Invested Capital and Return on Invested Capital

ROCE - Return on Capital Employed (TTM)

i

EBIT, Capital Employed and Return on Capital Employed

Asset Turnover (TTM)

i

Revenue, Total Assets and Turnover Ratio

CapEx/Depreciation - Investment Intensity (TTM)

i

CapEx, Depreciation and Ratio (>1=Expansion, <1=Contraction)

R&D/Gross Profit - R&D Intensity (TTM)

i

R&D Expenses, Gross Profit and Ratio

SG&A/Revenue - SG&A Efficiency (TTM)

i

SG&A Expenses, Revenue and Ratio

Cash Conversion Cycle (TTM)

i

DSO + DIO - DPO (in days)

DSO - Days Sales Outstanding (TTM)

i

Average Receivables and Days Sales Outstanding

DIO - Days Inventory Outstanding (TTM)

i

Average Inventory and Days Inventory Outstanding

DPO - Days Payables Outstanding (TTM)

i

Average Payables and Days Payables Outstanding

Goodwill/Assets (Quarterly)

i

Goodwill as % of Total Assets

🎁 股东回报

股息、股票回购、稀释和内部人交易活动

Dividend Yield (TTM)

i

Dividend Per Share, Share Price and Dividend Yield

Buyback Yield (TTM)

i

Net Buyback and Buyback Yield

Buyback Yield (3 Years)

i

Net Buyback 3Y and Buyback Yield 3Y

Dilution Rate (1 Year)

i

Current Shares, 1Y Ago Shares and Dilution Rate

Dilution Rate (3 Years)

i

Current Shares, 3Y Ago Shares and Dilution Rate

SBC Offset Rate (TTM)

i

Buyback / Stock-Based Comp and SBC Ratio

Insider Activity Rate (TTM)

i

Insider Net Buying and Activity Rate

利润瀑布图分析

加载图表中...

P

盈利能力指标

Gross Profit Margini毛利率

83.54%

毛利润 = $12.53B

营业收入 = $15.00B

Operating Profit Margini营业利润率

31.56%

营业利润 = $4.73B

营业收入 = $15.00B

EBITDA MarginiEBITDA利润率

31.56%

EBITDA = $4.73B

营业收入 = $15.00B

EBIT MarginiEBIT利润率

31.56%

EBIT = $1.04B

营业收入 = $15.00B

Net Profit Margini净利率

4.66%

净利润 = $0.70B

营业收入 = $15.00B

Pretax Profit Margini税前利润率

6.93%

税前利润 = $1.04B

营业收入 = $15.00B

E

运营效率指标

Interest Coveragei利息保障倍数

4.18x

EBIT (TTM) = $11.86B

利息费用 (TTM) = $2.84B

2.3x

2.1x

1.6x

3.3x

4.2x

SG&A / Revenuei销管费率

23.85%

销售及管理费用 = $3.58B

营业收入 = $15.00B

R&D / Revenuei研发占比

0.00%

研发费用 = $0.00B

营业收入 = $15.00B

R

回报率指标 (TTM)

ROAi总资产回报率

2.67%

净利润 = $3.65B

平均总资产 = $136.31B

ROEi净资产收益率

25.21%

净利润 = $3.65B

平均股东权益 = $14.46B

ROICi投入资本回报率

14.25%

NOPAT (TTM) = $11.16B

平均投入资本 = $78.27B

(NOPAT = 营业利润 × (1 - 有效税率))

(平均投入资本 = (本期IC + 去年同期IC) / 2)

Revenue Growthi营收增长率

12.43%

当期营收 = $15.00B

去年同期营收 = $13.34B

+8.4%

+6.7%

+9.1%

+10.0%

+12.4%

Operating Cash Flow/Sharei每股经营现金流

$11.96

经营现金流 = $21.22B

流通股数 = 1.77B

$9.26

$10.88

$11.77

$10.73

$11.96

综合分析

利润表项目	同比增长	当季数据	趋势
营业收入	+12.4%	$15.00B	↑
毛利	+34.2%	$12.53B, 83.54%	↑
营业利润	+26.8%	$4.73B, 31.56%	↑
EBITDA	+7.6%	$4.73B, 31.56%	↑
税前利润	-37.4%	$1.04B, 6.93%	↓
净利润	-45.6%	$0.70B, 4.66%	↓
稀释每股收益	-45.8%	0.39	↓

加载图表中...

L

流动性指标

Current Ratioi流动比率

0.80

关注

流动资产 = $33.53B

流动负债 = $42.10B

Quick Ratioi速动比率

0.68

关注

速动资产 = $28.48B

流动负债 = $42.10B

Cash Ratioi现金比率

0.22

正常

现金及等价物 = $9.39B

流动负债 = $42.10B

Cash Ratio = (Cash + Short-term Investments) / Current Liabilities

L

杠杆指标

Debt to Equityi债务权益比

2.65

关注

总债务 = $72.86B

总权益 = $27.50B

Liabilities to Assetsi资产负债率 (总负债)

79.8%

关注

总负债 = $108.96B

总资产 = $136.46B

Equity Multiplieri权益乘数

4.96

关注

总资产 = $136.46B

总权益 = $27.50B

E

效率指标

Asset Turnoveri总资产周转率

0.46

关注

营收 (TTM) = $62.82B

平均总资产 = $136.31B

Inventory Turnoveri存货周转率

2.95

关注

营业成本 (TTM) = $14.73B

平均存货 = $5.00B

Receivables Turnoveri应收账款周转率

5.01

正常

营收 (TTM) = $62.82B

平均应收账款 = $12.53B

S

偿债能力

Interest Coveragei利息保障倍数

4.18

正常

EBIT (TTM) = $11.86B

利息费用 (TTM) = $2.84B

Net Debt to EBITDAi净债务/EBITDA

3.53

关注

净债务 = $63.47B

EBITDA (TTM) = $17.96B

Debt Service Coveragei偿债覆盖率

2.55

健康

经营现金流 (TTM) = $21.22B

债务偿付 = $8.33B

V

价值指标

Goodwill %i商誉占比

26.1%

关注

商誉 = $35.57B

总资产 = $136.46B

Working Capital Ratioi营运资本比率

-0.06

关注

营运资本 = $-8.57B

总资产 = $136.46B

现金流瀑布图

加载图表中...

流入

流出

小计

起止点

C

现金流指标

经营现金流 TTMi

$21.22B

自由现金流 TTMi

$20.86B

FCF = OCF - CapEx

经营现金流 (TTM) = $21.22B

资本支出 (TTM) = $-0.36B

自由现金流收益率i

5.84%

关注

FCF (TTM) = $20.86B

市值 = $357.52B

经营现金流/销售比i

33.79%

健康

经营现金流 (TTM) = $21.22B

营业收入 (TTM) = $62.82B

Q

质量与覆盖指标

收益质量i

5.82x

健康

经营现金流 (TTM) = $21.22B

净利润 (TTM) = $3.65B

现金流/债务比i

0.29x

正常

经营现金流 (TTM) = $21.22B

总负债 = $72.86B

短期覆盖率i

0.50x

正常

经营现金流 (TTM) = $21.22B

流动负债 = $42.10B

资本支出覆盖率i

59.12x

健康

经营现金流 (TTM) = $21.22B

资本支出 (TTM) = $0.36B

E

效率指标

⚡ 比率按USD计算，去除汇率影响

自由/经营现金流比i

98.31%

健康

自由现金流 (TTM) = $20.86B

经营现金流 (TTM) = $21.22B

资本支出/营收比i

0.57%

健康

资本支出 (TTM) = $0.36B

营业收入 (TTM) = $62.82B

净债务/EBITDAi

3.53

关注

净债务 = $63.47B

EBITDA (TTM) = $17.96B

G

增长指标

经营现金流增长率i

134.19%

健康

当期OCF (TTM) = $3.83B

上期OCF = $1.64B

股东盈余i

$11.32B

健康

净利润 (TTM) = $3.65B

+ 折旧摊销 (TTM) = $8.04B

- 资本支出 (TTM) = $-0.36B